La voie de signalisation P13K/AKT/mTOR = P13K/AKT / mTOR signalling pathwayDREYER, Chantal; RAYMOND, Eric; FAIVRE, Sandrine et al.Cancéro digest. 2009, Vol 1, Num 3, pp 187-189, issn 1953-5171, 3 p.Article

Voies de signalisation de la PI3K et de mTOR : perspectives de l'utilisation de la rapamycine et de ses dérivés en thérapie antitumorale ciblée = P13K and mTOR signalling pathways : perspectives for rapamycin and its derivatives as antineoplastic targeted therapiesDREYER, Chantal; FAIVRE, Sandrine; RAYMOND, Eric et al.Bulletin du cancer. 2006, Num AVR, pp 31-40, issn 0007-4551, 10 p., HSArticle

La nanotechnologie au service du cancer. Compte rendu des 9^èmes Biennales Monégasques de Cancérologie, Monaco, 20-23 janvier 2010BOISSEAU, Patrick; PIVOT, Xavier; RAYMOND, Eric et al.Oncologie (Paris). 2010, Vol 12, Num 4, issn 1292-3818, 14 p., SUP2Serial Issue

Gastrontestinal stromal tumor and carney's triadSPATZ, Alain; BRESSAC-DE PAILLERETS, Brigitte; RAYMOND, Eric et al.Journal of clinical oncology. 2004, Vol 22, Num 10, pp 2029-2031, issn 0732-183X, 3 p.Article

MEK in cancer and cancer therapyNEUZILLET, Cindy; TIJERAS-RABALLAND, Annemilaï; DE MESTIER, Louis et al.Pharmacology & therapeutics (Oxford). 2014, Vol 141, Num 2, pp 160-171, issn 0163-7258, 12 p.Article

Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancerDINGS, Ruud P. M; LEVINE, Joseph I; BROWN, Susan G et al.Investigational new drugs. 2013, Vol 31, Num 5, pp 1142-1150, issn 0167-6997, 9 p.Article

Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies : Targeting neuroendocrine tumor: mixing standard options with novel therapiesTIJERAS-RABALLAND, Annemilaï; NEUZILLET, Cindy; COUVELARD, Anne et al.Targeted oncology. 2012, Vol 7, Num 3, pp 173-181, issn 1776-2596, 9 p.Article

Thérapies ciblées dans le carcinome hépatocellulaire = Targeted therapies in hepatocellular carcinomaBOUATTOUR, Mohamed; MARIJON, Hélène; DREYER, Chantal et al.La Presse médicale (1983). 2010, Vol 39, Num 7-8, pp 753-764, issn 0755-4982, 12 p.Article

Temozolomide: A Safe and Effective Treatment for Malignant Digestive Endocrine TumorsMAIRE, Frédérique; HAMMEL, Pascal; RUSZNIEWSKI, Philippe et al.Neuroendocrinology (Basel). 2009, Vol 90, Num 1, pp 67-72, issn 0028-3835, 6 p.Article

Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic DataTANAKA, Chiaki; O'REILLY, Terence; HATTENBERGER, Marc et al.Journal of clinical oncology. 2008, Vol 26, Num 10, pp 1596-1602, issn 0732-183X, 7 p.Article

Rationale for targeted therapies in hepatocellular carcinomaFAIVRE, Sandrine; DREYER, Chantal; EL MAALOUF, Ghassan et al.Targeted oncology. 2008, Vol 3, Num 2, pp 81-85, issn 1776-2596, 5 p.Article

Locoregional effects of pegylated liposomal doxorubicin (Caelyx®) in irradiated area: A phase I-II study in patients with recurrent squamous cell carcinoma of the head and neckFAIVRE, Sandrine; ALSABE, Hassan; DJAFARI, Latifa et al.European journal of cancer (1990). 2004, Vol 40, Num 10, pp 1517-1521, issn 0959-8049, 5 p.Article

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancerRAYMOND, Eric; ALEXANDRE, Jérome; FAIVRE, Sandrine et al.Journal of clinical oncology. 2004, Vol 22, Num 12, pp 2336-2347, issn 0732-183X, 12 p.Article

Chimiothérapie par une association de cisplatine, carboplatine et 5-fluoro-uracile-acide folinique, suivie de chimioradiothérapie dans les cancers de l'oesophage inopérables = Chemotherapy with cisplatinum, carboplatin and 5FU-folinic acid, followed by concomitant chemo-radiotherapy in unresectable esophageal carcinomasHENNEQUIN, Christophe; SALEMKOUR, Augustin; MAL, Frédéric et al.Bulletin du cancer. 2001, Vol 88, Num 2, pp 203-207, issn 0007-4551Article

OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesisASTORGUES-XERRI, Lucile; RIVEIRO, Maria E; FAIVRE, Sandrine et al.European journal of cancer (1990). 2014, Vol 50, Num 14, pp 2463-2477, issn 0959-8049, 15 p.Article

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III TrialCHENG, Ann-Lii; KANG, Yoon-Koo; OMATA, Masao et al.Journal of clinical oncology. 2013, Vol 31, Num 32, pp 4067-4075, issn 0732-183X, 9 p.Conference Paper

Traitements systémiques en phase avancée et en récidive après transplantation = Systemic therapies for advanced stage and for recurrence after liver transplantationBOUATTOUR, Mohamed; MATEESCU, Christian; DREYER, Chantal et al.Hépato-gastro & oncologie digestive. 2012, Vol 19, pp 46-54, issn 2115-3310, 9 p., SUP1Article

Les inhibiteurs de mTOR: Utilisation en cancérologieDREYER, Chantal; DELBALDO, Catherine; BOUATTOUR, Mohamed et al.Onko +. 2011, Vol 3, Num 20, pp 57-60, issn 2101-9495, 4 p.Article

Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignanciesFAIVRE, Sandrine; DELBALDO, Catherine; BOIGE, Valérie et al.European journal of cancer (1990). 2008, Vol 44, Num 5, pp 674-682, issn 0959-8049, 9 p.Article

Evaluation de la pertinence des prescriptions d'anticancéreux comme modèle d'EPP : expérience pilote d'évaluation ciblée du bon usage du médicamentSINEGRE, Martine; LE GRAN, Jennifer; THEOU-ANTON, Nathalie et al.Revue hospitalière de France (Paris). 2007, Num 518, pp 49-52, issn 0397-4626, 4 p.Article

Preclinical and clinical development of novel agents that target the protein kinase C familySEROVA, Maria; GHOUL, Aïda; BENHADJI, Karim A et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 466-478, issn 0093-7754, 13 p.Article

Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells : Induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanismsCOUDRAY, Anne-Marie; LOUVET, Christophe; KORNPROBST, Michel et al.International journal of oncology. 2005, Vol 27, Num 2, pp 553-561, issn 1019-6439, 9 p.Article

Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomasRAYMOND, Eric; FAIVRE, Sandrine; WEISS, Geoffrey et al.Clinical cancer research. 2001, Vol 7, Num 5, pp 1171-1180, issn 1078-0432Article

Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancerBOIGE, Valérie; RAYMOND, Eric; FAIVRE, Sandrine et al.Journal of clinical oncology. 2000, Vol 18, Num 23, pp 3986-3992, issn 0732-183XArticle

Les carcinomes du nasopharynx = Nasopharynx carcinomaHASBINI, Ali; RAYMOND, Eric; CVITKOVIC, Esteban et al.Bulletin du cancer. 2000, pp 21-26, issn 0007-4551, SUP5Article